Cross-neutralization of Human Immunodeficiency Virus Type 1 and 2 and Simian Immunodeficiency Virus Isolates

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1992 Jun 1

PMID 1374810

Citations 22

Authors

M Robert-Guroff

K Aldrich

R Muldoon

T L Stern

G P Bansal

T J Matthews

P D Markham

R C Gallo

G Franchini

Affiliations

Soon will be listed here.

Abstract

In contrast to infrequent and low-titer cross-neutralization of human immunodeficiency virus type 1 (HIV-1) isolates by HIV-2- and simian immunodeficiency virus (SIV)-positive sera, extensive cross-neutralization of HIV-2NIH-Z, SIVMAC251, and SIVAGM208K occurs with high titer, suggesting conservation of epitopes and mechanism(s) of neutralization. The V3 regions of HIV-2 and SIV isolates, minimally related to the HIV-1 homolog, share significant sequence homology and are immunogenic in monkeys as well as in humans. Whereas the crown of the V3 loop is cross-reactive among HIV-1 isolates and elicits neutralizing antibodies of broad specificity, the SIV and especially HIV-2 crown peptides were not well recognized by cross-neutralizing antisera. V3 loop peptides of HIV-2 isolates did not elicit neutralizing antibodies in mice, guinea pigs, or a goat and together with SIV V3 peptides did not inhibit serum neutralization of HIV-2 and SIV. Thus, the V3 loops of HIV-2 and SIV do not appear to constitute simple linear neutralizing epitopes. In view of the immunogenicity of V3 peptides, the failure of conserved crown peptides to react with natural sera implies a significant role of loop conformation in antibody recognition. Our studies suggest that in addition to their grouping by envelope genetic relatedness, HIV-2 and SIV are neutralized similarly to each other but differently from HIV-1. The use of linear peptides of HIV-2 and SIV as immunogens may require greater attention to microconformation, and alternate subunit approaches may be needed in exploiting these viruses as vaccine models. Such approaches may also be applicable to the HIV-1 system in which conformational epitopes, in addition to the V3 loop, participate in virus neutralization.

Citing Articles

Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses.

Khanal S, Fennessey C, OBrien S, Thorpe A, Reid C, Immonen T J Virol. 2019; 94(1).

PMID: 31597757 PMC: 6912102. DOI: 10.1128/JVI.01420-19.

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes.

OBrien S, Swanstrom A, Pegu A, Ko S, Immonen T, Del Prete G PLoS Pathog. 2019; 15(4):e1007632.

PMID: 30943274 PMC: 6447185. DOI: 10.1371/journal.ppat.1007632.

Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies.

Sun Z, Yan L, Tang J, Qian Q, Lenberg J, Zhu D Virus Res. 2017; 243:75-82.

PMID: 29051051 PMC: 7114535. DOI: 10.1016/j.virusres.2017.10.011.

Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.

Maria Marcelino J, Borrego P, Rocha C, Barroso H, Quintas A, Novo C J Virol. 2010; 84(23):12429-36.

PMID: 20844029 PMC: 2976386. DOI: 10.1128/JVI.01102-10.

Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins.

Maria Marcelino J, Barroso H, Goncalves F, Silva S, Novo C, Gomes P J Clin Microbiol. 2006; 44(2):607-11.

PMID: 16455923 PMC: 1392652. DOI: 10.1128/JCM.44.2.607-611.2006.

References

Matsushita S, Robert-Guroff M, Rusche J, Koito A, Hattori T, Hoshino H . Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol. 1988; 62(6):2107-14. PMC: 253305. DOI: 10.1128/JVI.62.6.2107-2114.1988. View

Seiki M, Hattori S, Hirayama Y, Yoshida M . Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci U S A. 1983; 80(12):3618-22. PMC: 394101. DOI: 10.1073/pnas.80.12.3618. View

Gojobori T, Moriyama E, Ina Y, Ikeo K, Miura T, Tsujimoto H . Evolutionary origin of human and simian immunodeficiency viruses. Proc Natl Acad Sci U S A. 1990; 87(11):4108-11. PMC: 54056. DOI: 10.1073/pnas.87.11.4108. View

Javaherian K, Langlois A, LaRosa G, Profy A, Bolognesi D, Herlihy W . Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science. 1990; 250(4987):1590-3. DOI: 10.1126/science.1703322. View

Thali M, Olshevsky U, Furman C, Gabuzda D, Posner M, Sodroski J . Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol. 1991; 65(11):6188-93. PMC: 250310. DOI: 10.1128/JVI.65.11.6188-6193.1991. View

Werner A, Winskowsky G, Cichutek K, Norley S, Kurth R . Productive infection of both CD4+ and CD4- human cell lines with HIV-1, HIV-2 and SIVagm. AIDS. 1990; 4(6):537-44. DOI: 10.1097/00002030-199006000-00007. View

Franchini G, Markham P, Gard E, Fargnoli K, Keubaruwa S, Jagodzinski L . Persistent infection of rhesus macaques with a molecular clone of human immunodeficiency virus type 2: evidence of minimal genetic drift and low pathogenetic effects. J Virol. 1990; 64(9):4462-7. PMC: 247916. DOI: 10.1128/JVI.64.9.4462-4467.1990. View

Wilson C, Reitz Jr M, Aldrich K, Klasse P, Blomberg J, Gallo R . The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J Virol. 1990; 64(7):3240-8. PMC: 249544. DOI: 10.1128/JVI.64.7.3240-3248.1990. View

LaRosa G, Davide J, Weinhold K, Waterbury J, Profy A, Lewis J . Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science. 1990; 249(4971):932-5. DOI: 10.1126/science.2392685. View

10.

Letvin N, Daniel M, Sehgal P, Desrosiers R, Hunt R, Waldron L . Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science. 1985; 230(4721):71-3. DOI: 10.1126/science.2412295. View

11.

Rusche J, Javaherian K, McDanal C, Petro J, Lynn D, Grimaila R . Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A. 1988; 85(9):3198-202. PMC: 280171. DOI: 10.1073/pnas.85.9.3198. View

12.

Goudsmit J, Debouck C, Meloen R, Smit L, Bakker M, Asher D . Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A. 1988; 85(12):4478-82. PMC: 280453. DOI: 10.1073/pnas.85.12.4478. View

13.

Franchini G, Fargnoli K, Giombini F, Jagodzinski L, De Rossi A, Bosch M . Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone. Proc Natl Acad Sci U S A. 1989; 86(7):2433-7. PMC: 286927. DOI: 10.1073/pnas.86.7.2433. View

14.

Reitz Jr M, Wilson C, Naugle C, Gallo R, Robert-Guroff M . Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell. 1988; 54(1):57-63. DOI: 10.1016/0092-8674(88)90179-1. View

15.

Lifson J, Hwang K, Nara P, Fraser B, Padgett M, Dunlop N . Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science. 1988; 241(4866):712-6. DOI: 10.1126/science.2969619. View

16.

Bottiger B, Karlsson A, Andreasson P, Naucler A, Costa C, Biberfeld G . Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135). AIDS Res Hum Retroviruses. 1989; 5(5):525-33. DOI: 10.1089/aid.1989.5.525. View

17.

Nicol I, Dubouch P, Bernard J, Snart R, Jouffre R, Reveil B . Persistent HIV-2 infection of rhesus macaque, baboon, and mangabeys. Intervirology. 1989; 30(5):258-67. DOI: 10.1159/000150101. View

18.

Skinner M, Langlois A, McDanal C, McDougal J, Bolognesi D, Matthews T . Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol. 1988; 62(11):4195-200. PMC: 253851. DOI: 10.1128/JVI.62.11.4195-4200.1988. View

19.

Robert-Guroff M, Brown M, Gallo R . HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature. 1985; 316(6023):72-4. DOI: 10.1038/316072a0. View

20.

Fultz P, McClure H, Anderson D, Swenson R, Anand R, Srinivasan A . Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci U S A. 1986; 83(14):5286-90. PMC: 323936. DOI: 10.1073/pnas.83.14.5286. View